多模态MRI影像组学技术在脑胶质瘤诊断及放疗中的应用进展

doi:10.19854/j.cnki.1008-2425.2025.01.0011

摘要/Abstract

摘要： 脑胶质瘤是中枢神经系统中常见的恶性肿瘤,确定病理分级和分子亚型对该疾病的精准治疗和预后分析具有重要意义。影像组学是一个迅速发展的领域,它涉及从医学影像中提取定量指标,即所谓的影像组学特征。多模态MRI影像组学对脑胶质瘤的鉴别诊断、确定手术边界、预后判断、监测治疗效果级明确有无复发等具有重要意义,是形态成像诊断的重要补充。放疗是脑胶质瘤患者的重要治疗手段,利用影像学鉴别胶质瘤复发与放疗后变化包括假性进展和放射性坏死的临床影像学仍是重大挑战。本文综述了基于多模态MRI的影像组学技术在脑胶质瘤诊断和放疗中的应用。这些技术的结合为临床诊断提供了新工具,有助于提高诊断准确性和放疗后的预后可靠性。通过这些技术,医生可以更全面地了解患者病情,制定个性化治疗方案,从而有效改善患者的预后和生活质量。

关键词: 神经胶质瘤, 影像组学, 放射治疗, 胶质瘤诊断

中图分类号:

R739.41

李洲天, 王宏伟. 多模态MRI影像组学技术在脑胶质瘤诊断及放疗中的应用进展[J]. 立体定向和功能性神经外科杂志, 2025, 38(1): 56-62.

参考文献

[1] Louis DN,Perry A,Wesseling P,et al.The 2021 WHO classification of tumors of the central nervous system:a summary[J].Neuro-oncology,2021,23(8):1231~1251.
[2] Gritsch S,Batchelor TT,Gonzalez Castro LN.Diagnostic,therapeutic,and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system[J].Cancer,2022,128(1):47~58.
[3] Weller M,Van Den Bent M,Tonn JC,et al.European Association for Neuro-Oncology(EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas[J].Lancet Oncol,2017,18(6):e315~e329.
[4] Gurney-Champion OJ,Mahmood F,van Schie M,et al.Quantitative imaging for radiotherapy purposes[J].Radiother Oncol,2020,146:66~75.
[5] Thorwarth D.Functional imaging for radiotherapy treatment planning:current status and future directions-a review[J].Br J Radiol,2015,88(1051):20150056.
[6] Gaustad JV,Rofstad EK.Assessment of intratumor heterogeneity in parametric dynamic contrast-enhanced MR images:a comparative study of novel and established methods[J].Front Oncol,2021,11:722773.
[7] Choi HS,Kim AH,Ahn SS,et al.Glioma grading capability:comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI[J].KoreanJ Radiol,2013,14(3):487~492.
[8] 王国杰,刘莹,韩艳华,等.胶质瘤患者MRI参数Ktrans值和Ve值与血清IL-10、VEGF的交互作用及对脑胶质瘤分级的诊断[J].立体定向和功能性神经外科杂志,2024,37(1):11~16.
[9] Zhao J,Yang ZY,Luo B,et al.Quantitative evaluation of diffusion and dynamic contrast-enhanced MR in tumor parenchyma and peritumoral area for distinction of brain tumors[J].PLoS One,2015,10(9):e0138573.
[10] Qiu J,Tao ZC,Deng KX,et al.Diagnostic accuracy of dynamic contrast-enhanced magnetic resonance imaging for distinguishing pseudoprogression from glioma recurrence:a meta-analysis[J].Chin Med J,2021,134(21):2535~2543.
[11] Baine M,Burr J,Du Q,et al.The potential use of radiomics with pre-radiation therapy MR imaging in predicting risk of pseudoprogression in glioblastoma patients[J].J Imaging,2021,7(2):17.
[12] Lemarié A,Lubrano V,Delmas C,et al.The STEMRI trial:Magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma stem-like cells[J].Sci Adv,2023,9(44):eadi0114.
[13] Iwahashi H,Nagashima H,Tanaka K,et al.2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma[J].J Neurosurg,2023,139(2):355~362.
[14] Ding H,Velasco C,Ye H,et al.Current applications and future development of magnetic resonance fingerprinting in diagnosis,characterization,and response monitoring in cancer[J].Cancers,2021,13(19):4742.
[15] Badve C,Yu A,Dastmalchian S,et al.MR fingerprinting of adult brain tumors:initial experience[J].A JNR Am J Neuroradiol,2017,38(3):492~499.
[16] Dastmalchian S,Kilinc O,Onyewadume L,et al.Radiomic analysis of magnetic resonance fingerprinting in adult brain tumors[J].Eur J Nucl Med Mol Imaging,2021,48:683~693.
[17] Nuessle NC,Behling F,Tabatabai G,et al.ADC-based stratification of molecular glioma subtypes using high b-value diffusion-weighted imaging[J].J Clin Med,2021,10(16):3451.
[18] Breen WG,Aryal M P,Cao Y,et al.Integrating multi-modal imaging in radiation treatments for glioblastoma[J].Neuro Oncol,2024,26(Supplement_1):S17~S25.
[19] Pramanik PP,Parmar HA,Mammoser AG,et al.Hypercellularity components of glioblastoma identified by high b-value diffusion-weighted imaging[J].Int J Radiat Oncol Biol Phys,2015,92(4):811~819.
[20] Lu S,Ahn D,Johnson G,et al.Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors[J].American Journal of Neuroradiology,2003,24(5):937~941.
[20] LU S,AHN D,JOHNSON G,et al.Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors[J].AJNR Am J Neuroradiol,2003,24(5):937-941.
[21] Scola E,Del Vecchio G,Busto G,et al.Conventional and advanced magnetic resonance imaging assessment of non-enhancing peritumoral area in brain tumor[J].Cancers,2023,15(11):2992.
[21] Scola E,DEL Vecchio G,Busto G,et al.Conventional and advanced magnetic resonance imaging assessment of non-enhancing peritumoral area in brain tumor[J].Cancers(Basel),2023,15(11):2992.
[22] Wang ZL,Guan FZ,Duan WC,et al.Diffusion tensor imaging‐based machine learning for IDH wild‐type glioblastoma stratification to reveal the biological underpinning of radiomic features[J].CNS Neurosci Ther,2023,29(11):3339~3350.
[23] Henriques R N,Jespersen S N,Jones D K,et al.Toward more robust and reproducible diffusion kurtosis imaging[J].Magn Reson Med,2021,86(3):1600~1613.
[24] Richter V,Nägele T,Erb G,et al.Improved diagnostic confidence and tumor type prediction in adult-type diffuse glioma by multimodal imaging including DCE perfusion and diffusion kurtosis mapping–A standardized multicenter study[J].Eur J Radiol,2024,171:111293.
[25] Minh Duc N.The effectiveness of diffusion kurtosis imaging metrics for distinguishing between brainstem glioma and cerebellar medulloblastoma[J].Clin Ter,2024,175(1):20~25.
[26] Genç B,Aslan K,Özçaĝlayan A,et al.Microstructural abnormalities in the contralateral normal-appearing white matter of glioblastoma patients evaluated with advanced diffusion imaging[J].Magn Reson Med Sci,2024,23(4):479~486.
[27] Hempel JM,Brendle C,Adib SD,et al.Glioma-specific diffusion signature in diffusion kurtosis imaging[J].J Clin Med,2021,10(11):2325.
[28] Omari EA,Zhang Y,Ahunbay E,et al.Multi‐parametric magnetic resonance imaging for radiation treatment planning[J].Med Phys,2022,49(4):2836~2845.
[29] Islam KT,Wijewickrema S,O'Leary S.A deep learning based framework for the registration of three dimensional multi-modal medical images of the head[J].Sci Rep,2021,11(1):1860.
[30] Bielak L,Wiedenmann N,Berlin A,et al.Convolutional neural networks for head and neck tumor segmentation on 7-channel multiparametric MRI:a leave-one-out analysis[J].Radiat Oncol,2020,15(1):181
[31] Koike Y,Akino Y,Sumida I,et al.Feasibility of synthetic computed tomography generated with an adversarial network for multi-sequence magnetic resonance-based brain radiotherapy[J].J Radiat Res,2020,61(1):92~103.
[32] Iancu RI,Zara AD,Mirestean CC,et al.Radiomics in head and neck cancers radiotherapy.promises and challenges[J].Maedica,2021,16(3):482~488.
[33] Ellingson BM,Malkin MG,Rand SD,et al.Validation of functional diffusion maps(fDMs) as a biomarker for human glioma cellularity[J].Magnetic Resonance Imaging:2010,31(3):538~548.
[34] Nakamura H,Murakami R,Hirai T,et al.Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy[J].Acta Radiol,2013,54(2):214~220.
[35] Hein PA,Eskey CJ,Dunn JF,et al.Diffusion-weighted imaging in the follow-up of treated high-grade gliomas:tumor recurrence versus radiation injury[J].AJNR Am J Neuroradiol,2004,25(2):201~209.
[36] Chang PD,Chow DS,Yang PH,et al.Predicting glioblastoma recurrence by early changes in the apparent diffusion coefficient value and signal intensity on FLAIR images[J].AJR Am J Roentgenol,2017,208(1):57~65.
[37] Zamanian M,Abedi I,Danazadeh F,et al.Multi-parametric magnetic resonance imaging assessment of response to chemo-radiotherapy in tumors of glioma cell types:a prospective study[J].2022.